PR Newswire·Sep 14, 2026, 6:45 AM ET

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share & pre-funded warrants for 9,078,529 shares at $22.029 per share.
Gross proceeds from the offering are expected to be approximately $400 million before deducting underwriting discounts & expenses.
The offering is scheduled to close on September 15, 2026, subject to customary closing conditions.
Net proceeds will fund the "dabogratinib 3x3" development strategy for LG-UTUC, IR NMIBC, & achondroplasia, alongside preclinical programs & general corporate purposes.
RA Capital Management led the offering with participation from institutional investors including Invus, Commodore Capital, BVF Partners, Janus Henderson Investors, Trails Edge Capital Partners, Integral Health Asset Management, TCGX, & StemPoint Capital LP.
Jefferies, Guggenheim Securities, Cantor, Barclays, & William Blair served as joint book-running managers; Wedbush PacGrow, Raymond James, & Oppenheimer & Co. acted as lead managers.
The shares were offered pursuant to a Form S-3 shelf registration statement that became effective on September 14, 2026.
Tyra Biosciences is a clinical-stage biotechnology firm based in Carlsbad, California, focused on FGFR biology & developing precision medicines like dabogratinib, TYRA-430, & TYRA-200.